 |
1 Product |  |
31 Diseases | | 1 Product |
|
0 Trials |  |
18 News |  |
- | JVS-100 / Astellas
Journal: Intra-tracheal administration of a naked plasmid expressing stromal derived factor-1 improves lung structure in rodents with experimental bronchopulmonary dysplasia. (Pubmed Central) - Apr 30, 2020
Intratracheal administration of a naked plasmid expressing SDF-1 improves alveolar and vascular structure in an experimental model of BPD. These findings suggest that therapies which modulate lung SDF-1 expression may have beneficial effects in preterm infants with BPD.
- | JVS-100 / Astellas
Clinical, Journal: SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial. (Pubmed Central) - Aug 15, 2019
P2b
...Using a novel design, we examined the impact of complementing revascularization therapy with intramuscular JVS-100 - a non-viral gene therapy that activates endogenous regenerative repair pathways...Only one-quarter of CLI wounds healed at 3 months despite successful revascularization, highlighting the need for additional research in therapies that can improve microcirculation in these patients. ClinicalTrials.gov Identifier: NCT02544204.
- |||| JVS-100 / Astellas
Enrollment open, Metastases: STOP-PAD: SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease (clinicaltrials.gov) - Dec 10, 2015
P2b, N=120, Recruiting, Sponsor: Juventas Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02544204. Not yet recruiting --> Recruiting
- |||||| JVS-100 / Astellas
New P2b trial, Metastases: STOP-PAD: SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease (clinicaltrials.gov) - Sep 9, 2015
P2b, N=120, Not yet recruiting, Sponsor: Juventas Therapeutics, Inc.
- ||| JVS-100 / Astellas
Enrollment closed, Trial primary completion date: RETRO-HF: Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure (clinicaltrials.gov) - Oct 23, 2014
P1/2, N=72, Active, not recruiting, Sponsor: Juventas Therapeutics, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Aug 2015
- | JVS-100 / Astellas
Trial completion: Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia (clinicaltrials.gov) - Oct 23, 2014
P2, N=48, Completed, Sponsor: Juventas Therapeutics, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Aug 2015 Active, not recruiting --> Completed
- |||| JVS-100 / Astellas
Enrollment open: RETRO-HF: Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure (clinicaltrials.gov) - Nov 10, 2013
P1/2, N=72, Recruiting, Sponsor: Juventas Therapeutics, Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||| JVS-100 / Astellas
Enrollment closed: STOP-HF: Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure. (clinicaltrials.gov) - Nov 10, 2013
P2, N=90, Active, not recruiting, Sponsor: Juventas Therapeutics, Inc.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | JVS-100 / Astellas
Enrollment closed: Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia (clinicaltrials.gov) - Nov 10, 2013
P2, N=48, Active, not recruiting, Sponsor: Juventas Therapeutics, Inc.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||||| JVS-100 / Astellas
New P1/2 trial: RETRO-HF: Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure (clinicaltrials.gov) - Oct 9, 2013
P1/2, N=72, Recruiting, Sponsor: Juventas Therapeutics, Inc.
- JVS-100 / Astellas
Enrollment change: Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy (clinicaltrials.gov) - Jul 21, 2013
P1, N=25, Recruiting, Sponsor: SironRX Therapeutics, Inc.
Recruiting --> Active, not recruiting N=48 --> 25
- | JVS-100 / Astellas
New P1 trial: Study to Evaluate the Safety and Efficacy of Dermal Injections of JVS-100 Given to Adults Receiving Median Sternotomy (clinicaltrials.gov) - Aug 1, 2012
P1, N=25, Recruiting, Sponsor: SironRX Therapeutics, Inc.
- ||||| JVS-100 / Astellas
New P2 trial: STOP-HF: Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure. (clinicaltrials.gov) - Jul 16, 2012
P2, N=90, Active, not recruiting, Sponsor: Juventas Therapeutics, Inc.
- | JVS-100 / Astellas
Trial completion: Study to Evaluate the Safety of a Single Escalating Dose of ACRX-100 in Adults With Ischemic Heart Failure (clinicaltrials.gov) - Jun 4, 2012
P1, N=17, Completed, Sponsor: Juventas Therapeutics, Inc.
N=48 --> 25 Active, not recruiting --> Completed
- | JVS-100 / Astellas
Trial initiation date: Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Critical Limb Ischemia (clinicaltrials.gov) - Mar 19, 2012
P2, N=48, Active, not recruiting, Sponsor: Juventas Therapeutics, Inc.
Active, not recruiting --> Completed Initiation date: Oct 2011 --> Mar 2012